Premium
Benchmarking biomarker‐based criteria for Alzheimer's disease: Data from the Swedish Dementia Registry, SveDem
Author(s) -
Rosén Christoffer,
Farahmand Bahman,
Skillbäck Tobias,
Nägga Katarina,
Mattsson Niklas,
Kilander Lena,
Religa Dorota,
Wimo Anders,
Blennow Kaj,
Winblad Bengt,
Zetterberg Henrik,
Eriksdotter Maria
Publication year - 2015
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2015.04.007
Subject(s) - biomarker , dementia , medicine , oncology , disease , cerebrospinal fluid , pathology , biochemistry , chemistry
New research guidelines for the diagnosis of Alzheimer's disease (AD) include biomarker evidence of amyloid‐β (Aβ) and tau pathology. The aim of this study was to investigate what proportion of AD patients diagnosed in clinical routine in Sweden that had an AD‐indicative cerebrospinal fluid (CSF) biomarker profile. Methods By cross‐referencing a laboratory database with the Swedish Dementia Registry (SveDem), 2357 patients with data on CSF Aβ and tau biomarkers and a clinical diagnosis of AD with dementia were acquired. Results Altogether, 77.2% had pathologic Aβ 42 and total tau or phosphorylated tau in CSF. These results were stable across age groups. Female sex and low mini‐mental state examination score increased the likelihood of pathologic biomarkers. Discussion About a quarter of clinically diagnosed AD patients did not have an AD‐indicative CSF biomarker profile. This discrepancy may partly reflect incorrect (false positive) clinical diagnosis or a lack in sensitivity of the biomarker assays.